Inside this episode
- Did NFL off-field drama impact my fantasy team?
- Would you go on a spacewalk?
- Why the markets are ignoring today's PPI data
- My expectations for a rate cut have changed
- I avoided this asset in the past—but now I'm incredibly bullish
- Breaking down Moderna's fall from grace
- Pfizer is the "Intel of pharma"—and that’s not good
- Proof the AI growth story isn’t slowing down
This week's trade
You’re undoubtedly familiar with this week’s pick…
It’s a tech darling that’s been dominating financial media headlines thanks to its remarkable surge higher over the past year or so.
In fact, you might think you’ve already missed the boat on the high-flying market leader…
But this growth story still has a ton of room to run as the AI revolution unfolds.
Better yet, a recent pullback in shares has created a rare trade opportunity—but it won’t last for long…